Artwork

Innhold levert av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)

3:00
 
Del
 

Manage episode 428438423 series 3017434
Innhold levert av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Listen to an audio podcast of the December 19, 2019 FDA Drug Safety Communication warning that serious breathing difficulties may occur in patients using seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors.
  continue reading

62 episoder

Artwork
iconDel
 
Manage episode 428438423 series 3017434
Innhold levert av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Listen to an audio podcast of the December 19, 2019 FDA Drug Safety Communication warning that serious breathing difficulties may occur in patients using seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors.
  continue reading

62 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett